Clinical trial

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

NCT01776684

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2012-06-01

PhaseNA

Study timeline

Study start (unknown)2012-06-01Date precision: month

Registry last updated2013-01-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

EGFR Mutation Positive Non-small Cell Lung Cancerunresolved

Interventions

EGFR TKIs (gefitinib, erlotinib, afatinib, et al)DRUG

Sponsors & collaborators

Samsung Medical Centerlead sponsor

AstraZenecacollaborator

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01776684 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.